
Opinion|Videos|September 1, 2023
Follow-Up Efficacy Data of Imetelstat in Lower-Risk MDS
Author(s)Eytan M. Stein, MD
Eytan M. Stein, MD, reviews recent follow-up data from the IMerge trial investigating imetelstat in patients with lower-risk myelodysplastic syndrome.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC Indications
2
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
3
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
4
Long-Term ECHO Data Support Concurrent Acalabrutinib/BR in MCL
5













































